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At a public hospital in Georgetown, Guyana, 44 patients seeking treatment for symptomatic, slide-conrmed
malaria were given standard chloroquine (CQ) therapy and followed for 28 days. The patients apparently had
pure infections with Plasmodium falciparum (14), P. vivax (13) or P. malariae (one), or mixed infections either of
P. falciparum and P. vivax (17) or of P. falciparum, P. malariae and P. vivax (two). Each received supervised
treatment with 10 mg CQ base/kg on each of days 0 and 1, and 5 mg/kg on day 2. On the day of enrollment
(day 0), the patients complained of fever (100%), headache (100%), malaise (94%), myalgia (79%), nausea
(67%), vertigo (49%) and vomiting (33%). Many (39%) were ill enough to conne themselves to bed. On day 4,
fewer of the subjects complained of fever (15%), headache (15%), malaise (6%), myalgia (21%), nausea (6%),
vertigo (24%) or vomiting (0%) despite the relatively high (>48%) risk of therapeutic failure. The cumulative
incidence of parasitological failure against P. falciparum was 15% at day 4, 33% at day 7 and 48% at day 14. All
of the P. vivax and P. malariae infections cleared before day 4 and none recurred by day 7. Two infections with
P. vivax recurred later (on day 14 or 28) but in the presence of less than adequate, whole-blood concentrations
of CQ plus desethyl-chloroquine (i.e.<100 ng/ml ). Taken together, the results indicate a high risk of therapeutic
failure of CQ against P. falciparum but also indicate that resistance to CQ in P. vivax occurs infrequently in Guyana.
The proliferation of drug-resistant strains distribute the recommended antimalarials at
of Plasmodium is complicating the develop- subsidized costs. These prescribed medicines
ment of national policies for the treatment often dene consumer preferences in the
of malaria in the developing world. Such private sector. In the developed world, an
policies often translate to widespread clinical array of antimalarials gives health-care pro-
practice because governments purchase and viders options suited to individual patients
and the probable sensitivity of the infections
they have acquired. In contrast, patients in
Reprint requests to: J. K. Baird.
impoverished, rural, endemic areas almostE-mail: bairdjk@namru2.med.navy.mil; fax: +62 21
424 4507. always receive the drugs recommended
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by the government. Thus, treatment-policy adults who are either local residents who
have recently visited the ‘frontier’ interiordecisions made by public-health oYcers in
endemic regions directly impact the clinical or residents of the interior who are visiting
Georgetown.management of malaria in the vast majority
of people infected.
In Guyana, the government abandoned
chloroquine (CQ) as rst-line therapy against SUBJECTS AND METHODS
P. falciparum in the early 1990s. Complaints
of frequent therapeutic failure from doctors Study Site and Subjects
A treatment trial was initiated in Septemberprompted the decision to adopt the com-
bination of quinine and pyrimethamine– 1998 using the fever clinic at Georgetown
Public Hospital in Georgetown, Guyana.sulfadoxine as rst-line therapy. Recom-
mendedquinine therapy requires three doses This clinic served as a referral centre for
patients suspected of having malaria. Thedaily for 7 days. The drug causes ringing in
the ears of most of those treated, as well as clinic typically processed 30–50 patients/
day, and 30%–50% of these usually provedvertigo and nausea. It is poorly tolerated and
inadequate compliance with unsupervised slide-positive for P. falciparum or P. vivax
malaria (with approximately twice as manytherapy almost certainly occurs regularly.
The risk of recurrent parasitaemia as a con- P. falciparum infections as P. vivax). Thick
bloodsmears were stained with Giemsa andsequence of poor compliance with quinine
must be weighed against that attributable screened, under oil immersion at ×1000,
by Ministry of Health microscopists in theto resistance to CQ. Reliable data charac-
terizing the therapeutic response to CQ clinic. Only patients with uncomplicated,
slide-proven malaria were screened for enroll-should drive treatment-policy decisions on
alternative therapeutic strategies. ment in the trial; those with severe or com-
plicated malaria were referred for admissionPhillips et al. (1996) described a P. vivax
infection that had been acquired in Guyana to the hospital. Eligible volunteers were at
least 5 years old and agreed to remain in thebut failed to respond to CQ therapy. As
this case was reported at a time when CQ vicinity of Georgetown during the 28 days
of post-treatment follow-up. The require-remained the rst-line drug for P. vivax
malaria in Guyana, it led to a review of the ment to remain available during follow-up
caused the majority of the otherwise eligiblenational policy for the treatment of P. vivax
and the present trial of the CQ treatment of subjects to decline to participate. Informed
consent was provided in accordance withP. vivax. As no recent data from Guyana
adequately described the therapeutic response U.S. Navy regulations governing the use
of human subjects in medical researchof local P. falciparum infections to CQ, such
infections were also investigated. The treat- (SECNAVINST 3900.39B), and as approved
by sanctioned committees for the protectionment policies for uncomplicated,P. falciparum
and P. vivaxmalaria inGuyana, wheremalaria of human subjects at the Ministry of Health
in Guyana, and the Naval Medical Researchhas become increasingly prevalent since
the 1970s, were retrospectively evaluated. Center in Bethesda, Maryland. Subjects
were examined by a physician and submittedThe study was based in Georgetown, on the
northern coast, where malaria was virtually to venipuncture for collection of 12-ml
samples of whole blood. These samples wereeradicated in the 1950s by spraying with
DDT and the distribution of ‘chloro- used for the cryopreservation of parasites,
the nested PCR of small-subunit ribosomalquinized’ salt (Giglioli, 1951; Giglioli et al.,
1976). Malaria on the northern coast remains RNA (ssrRNA) for conrmation of diagnosis
(see below), and routine tests for deciency inrelatively rare (Rambajan, 1994) and virtually
all the cases seen in Georgetown are in glucose-6-phosphate dehydrogenase (G6PD).
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Conrmation of Screening Diagnosis administered another 10 mg/kg in the sub-
ject’s home or workplace. A nal dose, ofThe screening diagnoses based on the exam-
ination of Giemsa-stained thick bloodsmears 5 mg/kg, was likewise administered on the
following day.were later checked in the laboratory using
blood samples collected at enrollment. Con- HPLC was used to estimate CQ concen-
trations in whole-blood samples from sub-rmation included examination of Giemsa-
stained thin bloodsmears (for all 49 subjects jects with suspected CQ-resistant P. vivax
(Baird et al., 1997b).enrolled) and a PCR-based assay for the
18srRNA gene (for the 30 samples identied
under the microscope as positive for P. vivax).
For the assay, DNA was extracted, from Follow-up
Smears were prepared of blood samplesblood samples spotted onto FTA® gene
cards (Life Technologies, Rockville, MD), collected from the subjects on each of days
0–6, 11, 14, 18, 21 and 28 (for thoseusing a Chelex method (Kain and Lanar,
1991). The DNA was then subjected to two infected with P. falciparum) or on days 0,
2, 4, 7, 11, 14, 18, 21 and 28 (for thoserounds of PCR using the primers and ampli-
cation conditions described by Snounou infected with P. vivax). The level of any
parasitaemia ( parasites/ml) was estimated byet al. (1993). In brief, the rst round of PCR
employed two Plasmodium-specic primers counting parasites against 200 leucocytes,
on the thick smear, and multiplying the countto amplify the DNA of any Plasmodium sp.
present. In the second round, aliquots of by 40 (assuming each subject had 8000
leucocytes/ml). A member of the researchproduct from the rst round were placed
into four separate reaction vessels, each con- team visited each subject at his or her home
or workplace to collect each post-enrollmenttaining species-specic primers for unique
18srRNA sequences (Snounou et al., 1993). sample and check on the subject’s general
health. Subjects complaining of illness wereIn a slight deviation from the published pro-
cedure, the rst and second rounds of PCR brought to the clinic for prompt evaluation
by the physician on the research team.were run for 30 and 40 cycles, respectively.
The assays were performed in a 96-well Subjects with slide-conrmed parasitaemia
after day 3 received alternative therapy withformat that included genomic DNA from
P. falciparum and P. vivax (in distilled water) quinine and pyrimethamine–sulfadoxine.
For subjects without recurrent parasitaemia,as positive controls. Electrophoresis of each
of the nested products of the second round follow-up ended on day 28.
of PCR was performed in gels of either
3% NuSieve agarose (FMC BioProducts,
Rockland, ME) or 2% SeaKem agarose Statistical Analysis
Life tables were used to estimate the risks(FMC BioProducts). The gels were stained
with ethidium bromide. of CQ therapeutic failure for P. falciparum
and P. vivax (Baird et al., 1997a). Recurrent
parasitaemia was taken as evidence of thera-
peutic failure, regardless of clinical signs andTreatment
As part of the enrollment procedure on day 0, symptoms. Rescue therapy prompted by
an inter-current parasitaemia (i.e. with aeach subject was given uncoated tablets of
chloroquine phosphate (ResochinTM ; Bayer, Plasmodium sp. diVerent to that observed on
day 0) constituted a loss to follow-up. MixedLeverkusen, Germany) in the clinic, at a
dose 10 mg base/kg bodyweight. Each sub- infections contributed to the analysis of each
species. The rationale for interpreting theject was watched for 30 min after treatment
and dosing was repeated if vomiting occurred. in-vivo test of CQ resistance in P. vivax was
described by Baird et al. (1997a).The next day a member of the research team
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RESULTS schizonts containing six to 14 merozoites
each; variation in the sizes of the infected
erythrocytes, from smaller to larger thanSubjects
Table 1 summarizes the demographic and normal; and bizarre, grossly enlarged erythro-
cytes (with diameters two or three times thoseparasitological characteristics of the study
population. Overall, 49 subjects, all but nine of the uninfected erythrocytes), each con-
taining a multinucleated form of the para-of them male, were enrolled. Although
children were eligible, only one child (a girl site. For these infections, the PCR-based
diagnosis of P. vivax was taken to be correctwith P. falciparum) was enrolled. None of
the subjects had G6PD deciency. The for the purpose of reporting therapeutic
responses to CQ, and the presentation ofresults of the thin-smear examinations and
PCR-based assays indicated that, at enroll- results in this report reects this approach.
Wherever discrepancies occurred between thement, the subjects had pure infections with
Plasmodium falciparum (14), P. vivax (13) thin-smear-based diagnosis and the results
of the nested-PCR analysis, the latter wereor P. malariae (one), or mixed infections
either of P. falciparum and P. vivax (17) or assumed to be correct when estimating the
risks of therapeutic failure.of P. falciparum, P. malariae and P. vivax
(two).
Responses to Treatment
Diagnosis
Comparison of the results of subsequent Plasmodium falciparum
Six of the 33 subjects recorded as P. falciparumexaminations of thick and thin bloodsmears
and of the PCR-based assay with those of infections were lost to follow-up (i.e. they
could not be located at home or work) priorthe screening diagnosis demonstrated short-
comings in the initial thick-smear screen- to day 4, but all of the remaining 27 reached
the end-point of recurrent parasitaemia oring as the primary instrument of diagnosis
(Table 2). In brief, many (62%) of the 26 day 28 of follow-up. Of these 27 subjects
(see Table 3), four failed to clear theirinfections initially considered to be solely
of P. vivax were found to be mixtures of P. falciparum parasitaemias by day 4 and
were therefore given alternative treatment.P. vivax and P. falciparum. Five infections
initially identied as solely of P. vivax and Another 11 subjects cleared their para-
sitaemias by day 4 but had to be givenshowing nested-PCR results consistent with
P. vivax (or a mixture of P. vivax and alternative treatment because of recurrent
P. falciparum parasitaemia by day 7 (ve),P. falciparum) presented morphological char-
acteristics considered incompatible with a between days 8 and 14 (four) or on days 17
(one) or 28 (one). Thirteen of the 27 sub-microscopical diagnosis of P. vivax. These
infections showed: pigmented trophozoites; jects diagnosedwith P. falciparum did not have
TABLE 1. Demographic and parasitological characteristics of the study population
No. of subjects
With mixed Mean age and Mean day-0 parasitaemia
Initial diagnosis Studied Male Female infection (range) (years) and (range)* ( parasites/ml)
P. falciparum malaria 33 27 6 19 26 (10–63) 7380 (40–92,240)
P. vivax malaria 32 25 7 19 31 (18–55) 3980 (120–17,120)
P. malariae malaria 3 3 0 2 38 (33–42) 3880†
*Mean counts exclude the mixed infections.
†The count for the sole mono-infection.
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TABLE 2. Comparison of the results of the screening, based on thick bloodsmears, with those of the subsequent examination
of thin smears and the PCR-based assay, for all the subjects who were identied as having Plasmodium vivax infection
in the initial screening and then investigated by the PCR-based assay*
Results of:
Parasitaemia†
Thick-smear screening Thin-smear examination Nested PCR (trophozoites/ml)
P. falciparum+P. vivax P. vivax P. vivax 15,360
P. falciparum+P. vivax P. vivax P. vivax 120
P. vivax P. vivax P. vivax 6080
P. vivax P. vivax P. vivax 12,640
P. vivax P. vivax P. vivax 1280
P. vivax P. vivax P. vivax 640
P. vivax P. vivax P. vivax 1840
P. vivax P. vivax P. vivax 11,200
P. vivax P. vivax P. falciparum+P. vivax 1920
P. vivax P. vivax P. falciparum+P. vivax 1920
P. vivax P. vivax P. falciparum+P. vivax 9120
P. vivax P. vivax P. falciparum+P. vivax 4800
P. vivax P. falciparum+P. vivax P. falciparum+P. vivax 640
P. vivax P. falciparum+P. vivax P. falciparum+P. vivax 4000
P. vivax P. falciparum+P. vivax P. falciparum+P. vivax 720
P. vivax P. falciparum+P. vivax P. falciparum+P. vivax 160
P. vivax P. falciparum+P. vivax P. falciparum+P. vivax 560
P. vivax P. falciparum+P. vivax P. falciparum+P. vivax 1280
P. vivax P. falciparum+P. vivax P. falciparum+P. vivax 320
P. falciparum+P. vivax P. falciparum+P. vivax P. falciparum+P. vivax 1120
P. vivax P. vivax P. falciparum 1520
P. vivax P. malariae P. malariae 3880
P. vivax P. falciparum+P. malariae P. vivax+P. malariae+P. falciparum 560
P. vivax P. vivax+P. malariae P. vivax+P. malariae+P. falciparum 4960
P. vivax Indeterminate P. vivax 920
P. vivax Indeterminate P. vivax 2880
P. vivax Indeterminate P. vivax 6560
P. vivax Indeterminate P. falciparum+P. vivax 17,200
P. vivax P. falciparum+ indeterminate P. falciparum+P. vivax 9760
*No PCR data were produced for another ve subjects identied as having pure P. vivax infections (two) or
mixed P. vivax/P. falciparum infections (three) at the initial screening.
†Estimated from counts on the thick bloodsmears.
recurrent parasitaemia during the 28 days parasitaemias by day 4, >90% were free of
all physical complaints except arthralgia andof follow-up. None of the 27 subjects with
P. falciparum infection at enrollmentdeveloped dizziness by day 4.
an inter-current P. vivax parasitaemia. The
Figure illustrates the cumulative incidence of
P. falciparum after the standard CQ therapy. Plasmodium vivax
Three of the 32 subjects initially infectedThe risk of the therapeutic failure of CQ
against P. falciparum in Guyana was esti- with P. vivax were lost to follow-up before
day 4 (Table 3). Another eight, all withmated at 33% by day 7 and 48% by day 14.
Of the subjects found to be infected with mixed infections at enrollment, were with-
drawn because they had to be treated forP. falciparum at enrollment,>75% reported
relief from physical complaints within 4 days recurrentP. falciparum parasitaemia by day 14.
Although two more subjects had (slide- andof their rst dose of CQ (Table 4). Among
those subjects who cleared their P. falciparum nested-PCR-conrmed) recurrent P. vivax
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TABLE 3. Life tables for the therapeutic failure of chloroquine against Plasmodium falciparum and P. vivax*
Interval
Parasite (day) N i w IR CI
Plasmodium falciparum 0† 33 0 6 0 0
4 27 4 0 0.1482 0.1482
7 23 5 0 0.2174 0.3334
11 18 2 0 0.1111 0.4075
14 16 2 0 0.125 0.4816
18 14 1 0 0.0714 0.5186
21 13 0 0 0 0.5186
28 13 1 0 0.0769 0.5556
Plasmodium vivax 0† 32 0 3 0 0
4 31 0 2 0 0
7 29 0 2 0 0
11 27 0 1 0 0
14 26 1 3 0.0408 0.0408
18 22 0 0 0 0.0408
21 22 0 0 0 0.0408
28 22 1 0 0.0454 0.0844
*N is the number of subjects at risk in the interval, I the number of incident cases of therapeutic failure, w the
number of withdrawals due to loss to follow-up or parasitaemia with another species, IR the interval risk
{i/[N­(w/2)]}, and CI is the cumulative incidence {1­[(1­IR
a
)×(1­CI
b
)]} in which IR
a
is the current
interval risk and CI
b
the cumulative incidence of the prior interval.
†At enrollment.
TABLE 4. Resolution of clinical complaints following chloroquine treatment of the subjects with Plasmodium falciparum
infections
Day-4 frequency (%) among:
Day-0 frequency
Complaint (%) All subjects Those aparasitaemic on day 4
Sick 100 18 9
Febrile 100 15 9
Headache 100 15 6
Malaise 94 6 3
Muscle ache 79 21 9
Joint ache 76 24 15
Nausea 67 6 3
Dizziness 49 24 15
Vomiting 33 0 0
Diarrhoea 21 10 10
Disturbed vision 12 12 9
Conned to home 39 12 6
parasitaemia on day 14 or 28, each had DISCUSSION
a whole-blood concentration of CQ plus
desethyl-chloroquine on the day of recur- This report documents a substantial risk of
therapeutic failure of CQ among a smallrence (74 and 0 ng/ml) that was below the
minimum eVective concentration for P. vivax. sample of subjects infected with P. falciparum
in Guyana, South America. The sample onlyThese two cases of recurrent parasitaemia
were therefore considered consistent with represented a small proportion of the patients
reporting to the enrollment site becauseCQ-sensitive P. vivax.
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FIG. Cumulative risk of post-chloroquine, recurrent, Plasmodium falciparum parasitaemia in Guyana.
most such patients had been infected in the incidence was 55%). Plasmodium falciparum
in Guyana appears polarized with respectinterior of the country while working for a
living and wished to return to the interior as to CQ susceptibility, with resistant and
susceptible populations mixed in roughlyquickly as possible. That most of the subjects
were adult males is probably evidence that equal proportions. Approximately one half
of the infections recrudescedwithin 14 days,travel to (or residence in) the forested interior
is a dominant risk factor for infection among whereas the other half appeared completely
susceptible to CQ. This unusual pattern maypatients seeking treatment in Georgetown;
infection among populations resident in be a product of the termination, in the early
1990s, of the use of CQ as rst-line therapythe endemic interior occurs across all ages
(Rambajan, 1994). The present subjects against P. falciparum in Guyana, which pre-
sumably diminished the survival advantagerepresented people who had incidentally
planned on remaining in Georgetown for at of resistance to the drug. In the absence of
baseline data, however, this interpretationleast 28 days, usually for reasons related to
family activities. It seems unlikely that this represents just one of several possible
explanations.produced a sample bias with respect to risk
of therapeutic failure. The small sample of P. vivax evaluated in
this study failed to reveal any therapeuticNearly half (48%) of the P. falciparum
infections recurred within 14 days of the failure attributable to resistance to CQ.
Among the 32 subjects with P. vivax, onlyrst dose of CQ, with relatively few recur-
rences after day 14 (the 28-day cumulative two had recurrent P. vivax parasitaemia
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during 28 days follow-up, and both of these their recurrent parasitaemias). This nding
corroborates similar observations in Africahad inadequate blood concentrations of CQ
plus desethyl-chloroquine (<100 ng/ml) at and South–east Asia (HoVman et al., 1983;
Khoromana et al., 1986). However, CQthe time of the recurrence. If this sample
were representative of P. vivax in Guyana, therapy in the face of even a relatively
modest resistance has been associated withthe risk of resistance to CQ would be less
than one in 30 infections. Despite con- increased risk of malaria-attributable death
(Zucker et al., 1996; Trape et al., 1998).vincing evidence that CQ-resistant P. vivax
occurs in Guyana (Phillips et al., 1996), the The training of Ethiopian mothers to treat
their young children with CQ reducedresults of the present (albeit small-scale)
study indicate that, during late 1998, the mortality in the children by 40% (Kidane
and Morrow, 2000). In this case, ‘self-risk of therapeutic failure because of such
resistance was <5%. treatment’ with CQ was obviously better
than no treatment, but eVective alternativeThe primary therapy currently recom-
mended for uncomplicated, P. falciparum therapy would avoid the unnecessary risk
of death resulting from parasitic resistancemalaria in Guyana is 7 days of quinine and
a single dose of pyrimethamine–sulfadoxine. to CQ. The ‘self-treating’ poor may not
appreciate such risk after clinical recovery,This was the regimen provided to the present
subjects who failed to clear their infections and they may fail to understand that CQ
therapy may exacerbate the transmissionwith CQ. Unfortunately, many of these
patients returned to the clinic within 2 weeks of malaria by creating asymptomatic but
infectious carriers. An eVective alternativeof their rst dose of quinine, all with
recurrent P. falciparum parasitaemia (data therapy that costs as little as CQ but has an
equally good safety and tolerance prolenot shown). As failure to comply with the
unsupervised regimen of quinine was the rule would be required to undermine the eco-
nomic forces that drive CQ use in the faceamong these subjects, this therapeutic strategy
suVers obvious shortcomings. However, there of resistance.
The data shown in Table 2 demonstrateare few if any practical alternatives available
to the local Ministry of Health. Neither the considerable inaccuracy in the initial screen-
ing diagnosis based on the examinationgovernment nor most residents of Guyana
possess the economic wherewithal to pur- of thick bloodsmears. Given the high risk of
CQ-resistant P. falciparum and the con-chase highly eVective and well-tolerated
antimalarials such as Lariam® (meoquine) tinued use of CQ as the rst-line treatment
for P. vivax infection in Guyana, the largeor Malarone® (atovaquone–proguanil).
Therapies involving artemisinin derivatives proportion of mixed P. vivax/P. falciparum
infections misdiagnosed as pure P. vivaxare not available. Uncomplicated,P. falciparum
malaria in Guyana appears to receive infections (62%) is worrisome. Many indi-
viduals infected with P. falciparum must beinadequate therapy often.
Despite the high risk of parasitological receiving only CQ therapy on the basis of a
P. vivax diagnosis at screening. The clinicfailure with CQ against P. falciparum, most
subjects infected with this parasite experi- where this study was conducted employed
two or three, full-time microscopists whoenced almost complete clinical recoverywithin
4 days of their rst dose of the drug (Table 4). essentially worked non-stop during the hours
of the clinic’s operation, to keep up withThis was especially true among those
who managed to clear their parasitaemias by the demand. The addition of thin-smear
reading, to increase the chances of detectingday 4. Most experienced rapid and sub-
stantial relief from illness despite the high P. falciparum in mixed infections, would very
substantially increase the workload and, likerisk of recurrence with symptoms (13 of
15 complained of being ill at the time of PCR-based assays, would not be practical
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with the available resources. The solution ment of CQ as the rst-line drug for such
disease. At the time of the present study,to the problems of poor compliance with
quinine and poor diVerentiation of species CQ apparently remained eVective for most
P. vivax acquired in Guyana, but otherby thick-smear-based diagnosis may be a
single, well tolerated alternative therapy evidence of CQ resistance in this species
merits surveillance of the problem. In viewthat is eVective against both P. falciparum
and P. vivax. Combined therapies merit of the high frequency of mixed infections of
P. falciparum and P. vivax not detectedexploration as possible solutions to this
problem. Furthermore, administering 45 mg by routine diagnostic procedures, an ideal
therapeutic regimenwould be eVective againstprimaquine weekly for 8 weeks would not
only achieve eVective transmission-blocking both species. Poor compliance with quinine
therapy for P. falciparum and the high risk ofbut also kill the liver stages of P. vivax. A
means of assuring compliance to this regimen undiagnosedP. falciparummixedwith P. vivax
being treated with CQ alone merits recon-would substantially improve protection of the
gains made against malaria on the coast of sideration of the national treatment policy.
Re-introduced endemic malaria threatensGuyana.
The northern coast of Guyana, where the heavily populated coastal region of
Guyana and addressing the threat requires>75% of the country’s population of about
700,000 live, has been largely free of malaria eVective treatment strategies. A Plasmodium
sp. in Guyana with an ssrRNA genesince a campaign of DDT spraying and
distribution of ‘chloroquinized’ salt during apparently indistinguishable from P. vivax,
but having consistent morphological charac-the 1950s and 1960s (Giglioli et al., 1976;
Rambajan, 1994). Nonetheless, the region teristics incompatible with that species, was
identied.remains receptive to endemic malaria. The
primary vector,Anopheles darlingi, has demon-
strated the ability to re-establish itself on the
coast and trigger outbreaks from infections acknowledgements. The study was sup-
ported by Veteran’s Administration grantintroduced by travellers from the interior
(Rambajan, 1987, 1988, 1994). Although (98-FRS-0273) to J.K.B. and S.L.H.,
STEP F, 6.2 and 6.3 of the MilitaryAn. darlingi (an eYcient vector) remains rare
in the coastal region, the ineYcient vector Infectious Diseases Research Program, the
Department of Defense Global EmergingAn. aquasalisoccurs in abundance (S. Rawlins,
unpubl. obs.). The ease of human travel Infections System, and the Pan American
Health Organization (PAHO) in Washington,between the malaria-free coastal region and
the malaria-endemic interior constitutes an DC. The views and opinions expressed
herein are those of the authors and do notobvious threat, and one that is amplied by
the apparent inadequacy of the available purport to reect or represent those of
the U.S. Navy or the U.S. Department oftherapy. At least three of the present subjects
apparently acquired their infections on the Defense. The authors gratefully acknowledge
the assistance and support of Dr R. Gusmaooutskirts of Georgetown (data not shown).
In the absence of eVective, unsupervised (PAHO,Washington) and V. Brown (PAHO,
Georgetown). The outstanding eVorts of thetherapy for malaria or a resumedapplication of
residual insecticides, endemic, CQ-resistant, Ministry of Health team in Georgetown
— especially L. Seelochan, O. Laine,P. falciparum malaria threatens to reclaim
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